Clinical Trials Sponsored by Vifor Pharma

Total 8282 results

Acesion Pharma

Recruiting

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969

Healthy Volunteers

Netherlands
Inozyme Pharma

Recruiting

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency

United States, United Kingdom, Canada
NervGen Pharma

Recruiting

NVG-291 in Spinal Cord Injury Subjects

Spinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord Injury

United States
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
Zealand Pharma

Recruiting

A Study to Inv. Safety,Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children<6 Years With T1D

Hypoglycemia

United States
LEO Pharma

Recruiting

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (DELTA TEEN)

Chronic Hand Eczema

Spain, France, Belgium, Australia, Canada, Poland, United Kingdom
Kiomed Pharma

Recruiting

Long-term Safety and Performance of KiOmedine CM-Chitosan Supplementation in Advanced Symptomatic Knee Osteoarthritis (PIONEER)

Osteoarthritis, Knee

Belgium
Amryt Pharma

Recruiting

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL (METRE-PL)

Partial Lipodystrophy

United States, Canada
Inozyme Pharma

Not yet recruiting

Natural History Study of ENPP1 Deficiency and and the Early-onset Form of ABCC6 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | ATP-Binding Cassette Subfamily C Member 6 Deficiency
MaaT Pharma

Recruiting

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)

Steroid Refractory GVHD | Intestinal GVHD

France
pH Pharma

Not yet recruiting

A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Korea, Republic of
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Advicenne Pharma

Not yet recruiting

Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children

Cystinuria

France, Belgium
Scandinavia Pharma

Recruiting

ORCA Study: Osteoarthritis and Risks Associated With the Consumption of NSAIDs (ORCA)

Osteoarthritis

Colombia
Scandinavia Pharma

Recruiting

Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD) (Epi-ERGE)

Gastroesophageal Reflux Disease

Colombia
Zealand Pharma

Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS (EASE SBS 2)

Short Bowel Syndrome

United States, France, Belgium, Denmark, United Kingdom, Germany, Canada, Italy, Netherlands, Poland
Acesion Pharma

Completed

A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

Atrial Fibrillation

Denmark, Hungary
NewAmsterdam Pharma

Completed

Randomized Study of Obicetrapib in Combination With Ezetimibe (OCEAN)

Dyslipidemias | Hypercholesterolemia | High Cholesterol

United States, Netherlands
LEO Pharma

Active, not recruiting

Investigating the Safety of LEO 158968 in Healthy Volunteers

Healthy Volunteers

Netherlands
UCB Pharma

Completed

A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).

Postherpetic Neuralgia
Zealand Pharma

Active, not recruiting

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Overweight | Healthy Volunteers | Obese

Germany
LEO Pharma

Completed

A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Stable Plaque Psoriasis

China
Advicenne Pharma

Terminated

Study Evaluating Subjects With Distal Renal Tubular Acidosis

Distal Renal Tubular Acidosis

United States, Canada
Advicenne Pharma

Withdrawn

Extension Study in Primary Distal Renal Tubular Acidosis

Acidosis, Renal Tubular

United States
LEO Pharma

Active, not recruiting

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Atopic Dermatitis

United States, Belgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Lumos Pharma

Active, not recruiting

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) (OraGrowtH210)

Growth Hormone Deficiency

United States, Australia, Israel, New Zealand, Poland, Ukraine
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
UCB Pharma

Completed

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Epilepsy, Partial
Athira Pharma

Active, not recruiting

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States
Zealand Pharma

Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Kiomed Pharma

Active, not recruiting

Evaluation of Performance and Safety of KIO015 in Face Skin Hydration Improvement (PLUM)

Skin Quality

France
Lumos Pharma

Active, not recruiting

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) (OraGrowtH212)

Growth Hormone Deficiency

Chile
UCB Pharma

Completed

Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.

Painful Diabetic Neuropathy

Russian Federation, Austria, Belgium, Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Romania, Serbia, Spain, United Kingdom
LEO Pharma

Completed

Tralokinumab Administered With Device A in Adults and Adolescents With Moderate-to-severe Atopic Dermatitis (INJECZTRA)

Atopic Dermatitis

United States
LEO Pharma

Completed

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Germany, Poland
Ellipses Pharma

Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Gastric Cancer | Small-cell Lung Cancer

China, Korea, Republic of, Taiwan
UCB Pharma

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease

United States, Canada, Finland, France, Israel, Russian Federation, Serbia, Tunisia
LEO Pharma

Completed

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Atopic Dermatitis

United States, Belgium, Canada, Australia, France, Germany, Japan, Netherlands, Poland, United Kingdom
Amryt Pharma

Active, not recruiting

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Homozygous Familial Hypercholesterolaemia (HoFH)

Germany, Israel, Italy, Saudi Arabia, Spain, Tunisia
AlzeCure Pharma

Completed

ACD440 Gel in Peripheral Neuropathic Pain

Peripheral Neuropathic Pain

Sweden
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
LEO Pharma

Completed

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

Germany
Zealand Pharma

Completed

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Overweight | Healthy Volunteers

Germany
Saffron Pharma

Completed

Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial

Acute Rhinosinusitis

Pakistan
LEO Pharma

Completed

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)

Atopic Dermatitis

United States, Canada
UCB Pharma

Completed

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

Epilepsy

United States, Czechia, Germany, Poland, Austria, Belgium, Brazil, Bulgaria, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation and more
LEO Pharma

Completed

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Atopic Dermatitis

United States
Anji Pharma

Completed

A Phase 1 Study of ANJ900 Chinese Healthy Subjects

Healthy

China

Clinical Trials Sponsored by Vifor Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations